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Abstract
Background: The aim of this work was to examine the prevalence of different metabolical phenotypes of obesity,
and to analyze, by using different risk scores, how the metabolic syndrome (MetS) definition discriminates between
unhealthy and healthy metabolic phenotypes in different obesity classes.
Methods: The Finnish type 2 diabetes (FIN-D2D) survey, a part of the larger implementation study, was carried out
in 2007. The present cross-sectional analysis comprises 2,849 individuals aged 45-74 years. The MetS was defined
with the new Harmonization definition. Cardiovascular risk was estimated with the Framingham and SCORE risk
scores. Diabetes risk was assessed with the FINDRISK score. Non-alcoholic fatty liver disease (NAFLD) was estimated
with the NAFLD score. Participants with and without MetS were classified in different weight categories and
analysis of regression models were used to test the linear trend between body mass index (BMI) and various
characteristics in individuals with and without MetS; and interaction between BMI and MetS.
Results: A metabolically healthy but obese phenotype was observed in 9.2% of obese men and in 16.4% of obese
women. The MetS-BMI interaction was significant for fasting glucose, 2-hour plasma glucose, fasting plasma insulin
and insulin resistance (HOMA-IR)(p < 0.001 for all). The prevalence of total diabetes (detected prior to or during
survey) was 37.0% in obese individuals with MetS and 4.3% in obese individuals without MetS (p < 0.001). MetS-
BMI interaction was significant (p < 0.001) also for the Framingham 10 year CVD risk score, NAFLD score and
estimated liver fat %, indicating greater effect of increasing BMI in participants with MetS compared to participants
without MetS. The metabolically healthy but obese individuals had lower 2-hour postload glucose levels (p =
0.0030), lower NAFLD scores (p < 0.001) and lower CVD risk scores (Framingham, p < 0.001; SCORE, p = 0.002) than
normal weight individuals with MetS.
Conclusions: Undetected Type 2 diabetes was more prevalent among those with MetS irrespective of the BMI
class and increasing BMI had a significantly greater effect on estimates of liver fat and future CVD risk among those
with MetS compared with participants without MetS. A healthy obese phenotype was associated with a better
metabolic profile than observed in normal weight individuals with MetS.
* Correspondence: pia.pajunen@thl.fi
† Contributed equally
1Diabetes Prevention Unit, Division of Welfare and Health Promotion,
National Institute for Health and Welfare, Helsinki, Finland
Full list of author information is available at the end of the article
Pajunen et al. BMC Public Health 2011, 11:754
http://www.biomedcentral.com/1471-2458/11/754
© 2011 Pajunen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Obesity is a major contributor to the global epidemic of
type 2 diabetes [1] to fatty liver disease [2] and to cardiovas-
cular diseases (CVD) [3]. Worldwide, at least 300 million
individuals are clinically obese [4] and in Finland, out of
those aged 25-74 years, 25% are obese and over half are
overweight [5].
Metabolic abnormalities which are usually associated
with obesity, do not, however, affect all obese people.
Approximately 10-25% of obese people [6] and a fraction
of morbidly obese individuals [7] are not affected by
metabolic disturbances [8-11]. These “metabolically
healthy but obese” subjects are insulin sensitive, have
normal blood pressure, a favorable lipid profile, a lower
proportion of visceral fat, less liver fat and a normal glu-
cose metabolism despite having an excessive amount of
body fat [9-17].
On the other hand, a subset of normal weight indivi-
duals suffer from metabolic disturbances that are charac-
teristic of obesity [18]. These individuals are called
“metabolically obese, normal weight individuals” [19,20].
Thus, obesity consists of different subtypes with different
metabolic profiles. Although these phenotypes have been
recognized by the scientific community, not much data
exists on the subject. It has been suggested that metaboli-
cally healthy obesity may have a less adverse metabolic
profile and outcome than normal weight individuals with
metabolic syndrome (MetS). However, there are only a
few studies comparing these phenotypes and giving the
true estimation of characteristics of these phenotypes in
the general population [8,19].
In this study, we examine the prevalence of different
metabolic phenotypes of obesity, especially the “metaboli-
cally healthy but obese” phenotype, and analyze, by using
different risk scores, how the MetS definition discrimi-
nates between unhealthy and healthy metabolic pheno-
types in different obesity classes in a large population-
based cohort of 2,849 individuals.
Methods
FIN-D2D survey
As part of evaluation of the implementation project of
the national type 2 diabetes prevention programme (FIN-
D2D), a survey was carried out in three hospital districts
in Finland between October and December 2007 [21]. A
random sample of 4,500 subjects aged 45-74 years, strati-
fied according to gender, 10-year age groups (45-54, 55-
64, and 65-74 years), and the three geographical areas,
was selected from the National Population Register. The
overall participation rate was 64%. In addition, 26 sub-
jects were excluded from the present analyses due to
missing data on variables needed for defining the MetS
(n = 17) or BMI (n = 19). The total number of individuals
included was thus 2,849 (63% of the original sample). The
study protocol was approved by the Ethical Committee of
the Hospital District of Helsinki and Uusimaa and all
participants gave their written and informed consent.
Clinical examination
Subjects were invited by mail to a clinical examination.
Together with the invitation, they also received a self-
administered questionnaire on medical history and health
behaviour. They were asked to complete the question-
naire at home, and bring it with them to the health
examination, which was carried out according to the
WHO MONICA project protocol [22]. At the study site,
trained nurses measured height, weight and waist cir-
cumference, as well as BP using a standardized protocol.
Height was measured to the nearest 0.1 cm. Body weight
of the participants wearing usual light indoor clothing
without shoes was measured with a 0.1 kg precision.
Blood pressure was measured twice in a sitting position
after a minimum of five minutes of acclimatization and
before blood sampling using a mercury sphygmoman-
ometer. The mean of the two blood pressure measure-
ments was used in the analyses.
Classification of obesity and the MetS
BMI was calculated as weight (kg) divided by height ×
height (m
2). Overweight and obesity were defined as BMI
25-29 kg/m
2 and ≥ 30 kg/m
2, respectively. The MetS was
defined according to the Harmonization definition [23],
which requires three or more of the following five compo-
nents: large waist circumference (≥ 94 cm in men and ≥
80 cm in women), hypertriglyceridemia (≥ 1.7 mmol/l),
HDL cholesterol level < 1.0 mmol/l in men or < 1.3
mmol/l in women, elevated blood pressure (systolic ≥ 130
mmHg and/or diastolic ≥ 85 mmHg and/) or antihyper-
tensive drug treatment or history of hypertension, elevated
fasting plasma glucose ≥ 5.6 mmol/l or drug treatment.
Glucose tolerance status
The glucose tolerance status was classified according to
the WHO 1999 criteria [24]. Individuals who already had
diagnosed type 2 diabetes were not included in the OGTT
and were classified as known diabetic participants. Indivi-
duals who had not been diagnosed as diabetic, but who
had a fasting plasma glucose level of ≥ 7.0 mmol/l or 2 h
plasma glucose ≥ 11.1 were classified as having screen-
detected type 2 diabetes. The known diabetic individuals
and the screen-detected diabetic individuals were com-
bined to create a group defined as total type 2 diabetics.
Biochemical measurements
All assays were performed at the Disease Risk Unit of the
National Institute for Health and Welfare, Helsinki, using
Architect ci8200 analyzer (Abbott Laboratories, Abbott
Park, IL, US). Plasma glucose was determined with a
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IL) and serum insulin with a chemiluminescent micro-
particle immunoassay (Abbott Laboratories, Abbott Park,
IL, US). Serum total and HDL cholesterol, and triglycer-
ide concentrations were measured with enzymatic kits
from Abbott Laboratories (Abbott Park, IL, US). The
lipoproteins apoA1 and apoB were determined with an
immunoturbidimetric method (Abbott Park, IL, US). The
concentrations of LDL cholesterol were calculated using
the Friedewald formula [25]. Serum ALT, AST, and gGT
concentrations were determined using photometric IFCC
(International Federation of Clinical Chemistry) methods
(Abbott Laboratories, Abbott Park, IL, US). High-sensi-
tivity C-reactive protein (hsCRP) was measured with an
immunoturbidimetric method (Sentinel Diagnostics,
Milano, Italy).
Risk scores
Cardiovascular risk was estimated with the Framingham
[26] and SCORE risk scores [27]. Diabetes risk was
assessed with the FINDRISK score [28]. Non-alcoholic
fatty liver disease (NAFLD) was estimated with the
NAFLD score [29].
Lifestyle definitions
The average daily alcohol consumption (g/d) was calcu-
lated from the self-reported number of drinks taken
during the past week.
The estimation of fruit and vegetable consumption was
derived from the question: “How often do you eat fruit,
vegetables and brown bread (rye- or whole-grain bread)?”
The possible answers were: 1) every day, and 2) not every
day. Fruit and vegetable consumption was considered
scarce if it did not occur daily.
Leisure time physical activity was estimated with the
question: “How much do you exercise or exert yourself
physically in your leisure time?” Endurance training
such as jogging or swimming at least 3 hours per week
was classified as “active”. Endurance training less than 3
hours per week was considered “inactive”.
Weight change during the past year was ascertained
from the question:” How much does your weight differ
from the weight you had one year ago?” The average
amount of sleep was calculated from the question:” How
many hours do you sleep on average each night?”
Statistical methods
Mean values with standard deviations and proportions
were used to describe the characteristics of different obe-
sity subgroups. For continuous variables, analysis of covar-
iance (ANCOVA) was used to test the linear trend
between BMI and various characteristics in individuals
with and without MetS, respectively. Similarly, logistic
regression models were used for analyses of dichotomous
variables. ANCOVA and logistic regression models were
further used to test the interaction between BMI and
MetS when considering the associations. All p-values are
two-sided and p < 0.05 was considered as statistically sig-
nificant. Statistical analyses were carried out using the
Stata statistical package 10.1 (Stata-Corp. 2007. Stata
Statistical Software: Release 10.1. College Station, TX;
StataCorp LP).
Results
A metabolically healthy but obese phenotype was
observed in 9.2% of obese men and in 16.4% of obese
women (Figure 1). Among all participants, the prevalence
of healthy obesity was 2.0% among men and 4.5% among
women. Of the normal weight individuals, 20.4% of men
and 23.8% of women had the MetS (Figure 1). MetS
increased with age in both sexes (data not shown).
Table 1 presents the distribution of the MetS definition
components by obesity class in persons with and without
MetS. Table 2 shows CVD risk factors, parameters
related to glucose metabolism and liver function as well
as lifestyle factors by obesity class in persons with and
without MetS. Overall, in all weight categories (normal
weight BMI < 25, overweight BMI 25-29.9, obese BMI ≥
30) individuals with MetS had a more adverse metabolic
profile and greater cardiovascular and diabetes risk scores
compared with the individuals without MetS (Tables 1
and 2).
Fasting plasma glucose levels were not modified by
increasing BMI among individuals without MetS (p =
0.589 for trend, Table 1), but 2-hour plasma glucose was
(p = 0.013 for trend, Table 2). Among participants with
MetS, there was a significant trend for both higher fasting
and 2-hour plasma glucose levels with increasing BMI
(p < 0.001 for both, Tables 1 and 2). MetS-BMI interac-
tion was significant for 2-hour plasma glucose, fasting
plasma insulin and HOMA-IR (< 0.001 for all) (Table 2).
The OGTT revealed a significantly higher proportion of
previously undetected type 2 diabetes among those with
MetS than among those without MetS irrespective of the
BMI class (7.9% vs. 3.4%, p = 0.006 in BMI < 25 class,
14.4% vs. 3.1%, p < 0.001 in BMI 25-29.9 class and 21.5%
vs. 4.3% in BMI ≥ 30 class). The prevalence of total dia-
betes (detected prior to or during survey) was 37.0% in
obese individuals with MetS and 4.3% in obese indivi-
duals without MetS (p < 0.001). MetS-BMI interaction
for the FINDRISK score was not significant whereas the
Framingham 10 year CVD risk score was significantly
higher in those with the MetS irrespective of the BMI
class (Table 2).
Increasing BMI had a greater effect on ALT (MetS-
BMI interaction p = 0.033), AST (MetS-BMI interaction
p = 0.045), NAFLD score (MetS-BMI interaction p <
0.001) and estimated liver fat % (MetS-BMI interaction
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out MetS (Table 2).
Leisure time physical activity diminished with increasing
BMI class irrespective of MetS classification (Table 2).
Leisure time physical activity did not differ between meta-
bolically healthy and metabolically abnormal obese indivi-
duals (14.1% vs. 12.1%, p = 0.591). There were no
differences in lifestyle variables, i.e. the daily consumption
of fruits and vegetables, daily length of sleep, cigarette
smoking, or reported alcohol consumption between the
individuals with and without MetS.
The survey included 205 individuals (80 men and 125
women) of normal weight who had MetS and 94 (27 men
and 67 women) obese individuals without MetS. The
metabolically healthy but obese individuals had lower
systolic and diastolic blood pressure levels than normal
weight individuals with MetS (139.2 ± 16.9 vs. 130.1 ±
16.7, p < 0.001 and 82.8 ± 8.8 vs. 79.2 ± 7.7, p = 0.0007).
The metabolically healthy but obese individuals had
l o w e r2 - h o u rp o s t l o a dg l u c o s el e v e l s( 6 . 5±2 . 1v s .7 . 1±
2.5 mmol/l, p = 0.0030) than normal weight individuals
with MetS. There was no difference in cholesterol or
LDL-cholesterol levels but the metabolically healthy but
obese individuals had lower triglyceride (1.2 ± 0.35 vs.
1.4 ± 0.68 mmol/l, p = 0.005) and higher HDL cholesterol
levels (1.5 ± 0.21 vs. 1.4 ± 0.38 mmol/l, p = 0.007) than
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Figure 1 Prevalence of persons with and without MetS within each BMI category among men (left panel) and among women (right
panel) (total 100% within the BMI class).
Table 1 Basic characteristics and components of the metabolic syndrome in individuals with and without metabolic
syndrome in different BMI classes
No MetS MetS
BMI < 25
No MetS
(n = 712)
BMI 25-29.9
No MetS
(n = 418)
BMI ≥ 30
No MetS
(n = 94)
P
trend
BMI < 25
MetS
(n = 205)
BMI 25-29.9
MetS
(n = 811)
BMI ≥ 30
MetS
(n = 609)
P
trend
P
MetS/
BMI
Interaction
Population prevalence, % 25.0 14.7 3.3 7.2 28.5 21.3
Proportion of men, % 43.8 48.6 28.7 39.0 57.6 44.2
Age (yr) 57.8 ± 8.5 57.6 ± 8.3 58.5 ± 8.2 0.801 60.3 ± 8.1 61.4 ± 7.8 61.3 ± 8.3 0.356 0.593
Height (cm) 168.7 ± 8.7 168.7 ± 8.6 165.8 ± 9.6 0.053 169.1 ± 9.3 170.3 ± 9.2 167.7 ± 9.0 < 0.001 < 0.001
Weight (kg) 64.4 ± 8.7 76.6 ± 8.4 91.4 ± 12.6 < 0.001 68.1 ± 8.5 80.1 ± 9.6 96.2 ± 15.0 < 0.001 0.003
MetS components
Waist (cm) 81.2 ± 7.5 91.8 ± 7.0 105.1 ± 9.7 < 0.001 88.4 ± 6.7 97.4 ± 7.5 111.1 ± 11.2 < 0.001 0.205
BMI (kg/m
2) 22.5 ± 1.7 26.9 ± 1.3 33.2 ± 3.1 < 0.001 23.7 ± 1.1 27.5 ± 1.3 34.1 ± 4.2 < 0.001 < 0.001
SBP (mmHg) 128.8 ± 18.1 127.2 ± 15.5 130.1 ± 16.7 0.589 139.2 ± 16.7 143.3 ± 17.5 144.7 ± 17.3 < 0.001 0.006
DBP (mmHg) 78.1 ± 9.3 78.8 ± 8.4 79.2 ± 7.7 0.077 82.8 ± 8.8 83.7 ± 9.2 84.8 ± 9.5 0.003 0.424
FPG (mmol/l) 5.8 ± 0.88 5.8 ± 0.94 5.8 ± 1.4 0.585 6.2 ± 0.85 6.5 ± 1.2 6.7 ± 1.4 < 0.001 < 0.001
Triglycerides (mmol/l) 0.96 ± 0.34 1.1 ± 0.34 1.2 ± 0.35 < 0.001 1.4 ± 0.68 1.6 ± 0.97 1.8 ± 1.0 < 0.001 < 0.001
HDL cholesterol (mmol/l) 1.6 ± 0.34 1.5 ± 0.31 1.5 ± 0.21 < 0.001 1.4 ± 0.38 1.4 ± 0.33 1.3 ± 0.27 < 0.001 0.029
BMI, body mass index; FPG, fasting plasma glucose; HDL cholesterol, high-density lipoprotein cholesterol; DBP, diastolic blood pressure;
SBP, systolic blood pressure. P values adjusted for age and sex (except p for age which is adjusted for sex only).
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No MetS MetS
BMI < 25
(n = 712)
BMI 25-29.9
(n = 418)
BMI ≥ 30
(n = 94)
P
trend
BMI < 25
(n = 205)
BMI 25-29.9
(n = 811)
BMI ≥ 30
(n = 609)
P
trend
P for MetS/BMI
Interaction
Glucose metabolism
2-hour plasma glucose (mmol/l) 6.0 ± 2.1 6.3 ± 1.8 6.5 ± 2.1 0.013 7.1 ± 2.5 7.6 ± 2.7 8.6 ± 3.4 < 0.001 < 0.001
fP-insulin (mU/l) 5.1 ± 4.4 6.0 ± 2.5 8.5 ± 4.2 < 0.001 6.7 ± 4.1 9.8 ± 22.0 14.7 ± 22.6 < 0.001 < 0.001
HOMA-IR 1.4 ± 2.5 1.6 ± 0.76 2.3 ± 2.4 0.001 1.8 ± 1.1 3.3 ± 15 4.7 ± 8.7 < 0.001 < 0.001
FINDRISK diabetes risk score (points) 6.6 ± 3.4 9.8 ± 3.4 13 ± 3.1 < 0.001 10.2 ± 4.0 12.5 ± 3.9 16 ± 4.1 < 0.001 0.518
Total T2DM, % 5.1 3.8 4.3 0.490 14.4 21.3 37.0 < 0.001 < 0.001
Previously diagnosed T2DM, % 1.7 0.7 0 0.064 6.4 6.9 15.5 < 0.001 0.002
T2DM, undetected prior survey, % 3.4 3.1 4.3 0.800 7.9 14.4 21.5 < 0.001 0.075
CVD risk
Cholesterol (mmol/l) 5.4 ± 0.86 5.5 ± 0.90 5.6 ± 0.98 0.001 5.6 ± 1.1 5.4 ± 1.0 5.4 ± 1.1 0.019 < 0.001
LDL cholesterol (mmol/l) 3.3 ± 0.76 3.5 ± 0.80 3.6 ± 0.87 < 0.001 3.5 ± 0.89 3.3 ± 0.89 3.3 ± 0.96 0.001 < 0.001
Apolipoprotein A1 (g/l) 1.7 ± 0.26 1.6 ± 0.24 1.6 ± 0.19 < 0.001 1.6 ± 0.30 1.5 ± 0.26 1.5 ± 0.23 < 0.001 0.985
Apolipoprotein B (g/l) 0.90 ± 0.19 0.97 ± 0.19 0.98 ± 0.19 < 0.001 1.0 ± 0.23 1.0 ± 0.23 1.0 ± 0.24 < 0.001 < 0.001
hsCRP (mg/l) 1.3 ± 3.8 2.5 ± 8.0 3.1 ± 4.6 < 0.001 3.8 ± 16 2.5 ± 5.0 4.4 ± 8.5 0.118 0.713
Framingham 10 yr CVD (%) 11.9 ± 11.1 11.3 ± 8.4 10.4 ± 8.6 0.067 18.7 ± 13.9 22.8 ± 15 25.1 ± 17.2 < 0.001 < 0.001
SCORE 10 yr fatal CVD (%) 4.5 ± 6.1 3.9 ± 4.3 3.6 ± 4.8 0.002 5.8 ± 5.9 7.2 ± 6.5 6.4 ± 5.8 0.560 0.074
Liver
Serum ALT (U/l) 21.1 ± 12.8 24.4 ± 10.6 24.6 ± 12.5 < 0.001 24.7 ± 15.4 28.1 ± 15.6 32.9 ± 24.9 < 0.001 0.033
Serum AST(U/l) 24.3 ± 12.4 24.4 ± 7.4 25.6 ± 9.4 0.145 26.1 ± 13.0 26.8 ± 10.7 39.6 ± 17.7 < 0.001 0.045
Serum gGT (U/l) 26.9 ± 27.8 32.0 ± 28.1 33.0 ± 31.8 0.001 40.9 ± 117.5 40.5 ± 45.7 49.5 ± 66.6 0.065 0.636
Alcohol (g/d) 8.2 ± 13 7.6 ± 12 5.8 ± 11 0.168 8.6 ± 24 8.6 ± 14 8.0 ± 13 0.860 0.522
NAFLD score -2.0 ± 0.96 -1.9 ± 0.57 -1.5 ± 0.84 < 0.001 -0.45 ± 1.0 0.021 ± 3.5 0.97 ± 3.6 < 0.001 < 0.001
Estimated liver fat (%) 2.1 ± 1.1 2.2 ± 0.69 2.7 ± 1.0 < 0.001 4.9 ± 2.2 5.6 ± 3.4 7.8 ± 5.1 < 0.001 < 0.001
Lifestyle
Not eating fruits/vegetables daily, % 18.3 20.0 18.1 0.535 20.2 23.9 19.8 0.548 0.404
Active leisure time physical activity, % 30.9 27.6 14.1 0.002 20.6 19.3 12.1 < 0.001 0.836
Weight change during past year (kg) -0.31 ± 0.46 0.43 ± 3.8 0.56 ± 6.9 0.015 0.2 ± 0.40 -0.03 -0.16 ± 5.7 0.588 0.108
Hours slept per night (hours) 7.2 ± 0.99 7.3 ± 1.0 7.4 ± 1.1 0.453 7.4 ± 1.1 7.3 ± 1.1 7.3 ± 1.2 0.795 0.449
Currently smoking, % 18.5 12.8 8.6 0.002 16.3 16.7 10.1 0.002 0.470
ALT: alanine aminotransferase; AST: aspartate aminotransferase; Framingham 10 yr CVD, Framingham 10-year risk score for fatal coronary events; HDL cholesterol, high-density lipoprotein cholesterol; HOMA-IR,
homeostasis model assessment of insulin resistance; hsCRP, high-sensitivity C-reactive protein; NAFLD: non-alcoholic fatty liver disease; SCORE 10 yr fatal CVD, SCORE risk score 10-year risk score for fatal coronary
events T2DM, type 2 diabetes mellitus; gGT: gamma glutamyltransferase. P values adjusted for age and sex.
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8the normal weight subjects with the MetS. No difference
was observed in the high-sensitivity CRP or liver enzyme
values (data not shown). The metabolically healthy but
obese individuals had higher scores in the FINDRISK dia-
betes risk test (13.3 ± 3.1 vs. 10.2 ± 4.0 points, p < 0.001),
but lower prevalence of current type 2 diabetes than the
normal weight subjects with MetS. The estimated 10-
year fatal CVD risk (Framingham 18.7% vs. 10.4%, p <
0.001 and SCORE 5.8 vs. 3.6%, p = 0.002) was higher in
the normal weight individuals with MetS than in metabo-
lically healthy but obese individuals. The NAFLD score
and estimated liver fat percentage (2.7 ± 1.0 vs. 4.9 ± 2.2,
p < 0.001) were lower in the metabolically healthy but
obese individuals than in normal weight individuals with
MetS.
Discussion
In this study we used the most recent criteria of the MetS
[23] to identify metabolically healthy obese individuals
and normal weight individuals with MetS. Among the
Finnish population aged 45-74 years, the prevalence of
the metabolically healthy but obese phenotype was 2.0%
among men and 4.5% among women. Of the obese,
about one tenth had the metabolically healthy phenotype.
As there are currently no international unified criteria for
defining healthy obesity, it is difficult to compare these
results with the studies from other countries. Indeed, the
prevalence estimates of the healthy obese phenotype vary
considerably from 3.3% to 43% depending on the criteria
used [6,8,14,30-34].
The clinical value, biological basis and usefulness of the
MetS has been severely debated [35]. In the present study,
the MetS definition discriminated well between unhealthy
and healthy metabolic phenotypes in different obesity
classes beyond those included in the MetS criteria. Among
those with the Mets, the OGTT which was performed as
part of the survey revealed a significantly higher propor-
tion of previously undetected type 2 diabetes irrespective
of BMI class. The MetS-BMI interaction was significant
for fasting glucose, 2-hour plasma glucose, fasting plasma
insulin and HOMA-IR, indicating that the metabolic con-
sequences of obesity seem to be more adverse among indi-
viduals with MetS. Furthermore, increasing BMI had a
significantly greater effect on estimates of liver fat among
those with the MetS compared with participants without
MetS. The average NAFLD liver fat score was lower in
those without MetS irrespective of BMI class. Not surpris-
ingly, NAFLD has previously been shown to predict type 2
diabetes independent of obesity [2].
In accordance with earlier data from the US [8], the
metabolically healthy but obese phenotype was associated
with an overall better metabolic profile than observed in
normal weight individuals with MetS. Obese individuals
without MetS had lower fasting plasma glucose and 2-
hour postload glucose levelst h a nn o r m a lw e i g h ti n d i v i -
duals with MetS. In addition, they had a better lipid
profile and lower CVD risk scores, less estimated liver fat
and less often previously undetected diabetes compared
with normal weight individuals with the MetS. In clinical
work, it is thus important not only to estimate the degree
of obesity but also the presence of metabolical abnormal-
ities which are present in a significant proportion of the
normal weight individuals.
Some studies from other countries have suggested that a
metabolically healthy but obese phenotype would be asso-
ciated with decreased risk of nonfatal and fatal cardiovas-
cular events [31,36]. This may lie behind the finding that
while CVD incidence has been declining in Finland during
the past decades [37], the mean BMI has increased signifi-
cantly [38,39]. MetS irrespective of BMI class may confer
increased CVD risk. Even though we do not have the data
to study future CVD risk in the present cross-sectional
analysis, we have recently shown [40] that the 2009 Har-
monization definition of MetS is a significant predictor of
future incident CVD and diabetes both in men and in
women. In the present study, the Framingham 10-year
fatal CVD risk score was significantly lower in individuals
without MetS than in those with MetS irrespective of BMI
class. As shown by other researchers [8,10,12] and
observed in the present study, the metabolically healthy
but obese individuals had a slightly less atherogenic lipid
profile than normal weight individuals with MetS. How-
ever, we did not have data on lipid subclasses or other
more detailed biomarkers. No difference was observed in
inflammation estimated with the highly sensitive CRP.
Longitudinal studies with long enough follow-up periods
are needed to reveal the long-term CVD risk related to dif-
ferent obesity phenotypes. However, unlike some earlier
data (31, 36), a recent Swedish study with a 30-year
follow-up, suggested that increased risk of CVD related to
healthy obesity may be detected after only 10 years of
follow-up [33].
Different mechanisms behind the different obesity phe-
notypes include genetic, socioeconomic and behavioral
factors, some of which may be modifiable [12,19,20].
In our study, obese individuals without MetS reported
similar amount of leisure time physical activity as did the
obese individuals with MetS.C o n t r a r yt oo u rf i n d i n g s ,a
US study found leisure time physical activity to be asso-
ciated with a metabolically healthy obese phenotype [8].
More advanced measures of physical activity may have
captured the possible differences in physical activity
between the groups in the present study. There were no
differences in sleeping patterns between any of
the groups. Neither could we detect any differences in
consumption of fruit and vegetables. However, more
sophisticated methods may be needed to estimate true
differences in dietary habits.
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unified criteria for definition of metabolically healthy
obesity are urgently needed [30]. These criteria should be
suitable for use in population surveys. In the present
study we used BMI and the most recent definition of
MetS to characterize metabolically healthy obesity. How-
ever, BMI does not take into account body composition
and amount of body fat. In addition to the need for a
definition of healthy obesity, there is a need to develop
valid and reliable methods of measuring body composi-
tion in population surveys.
T h es t r e n g t h so ft h ep r e s e n ts t u d yi n c l u d eap o p u l a -
tion-based approach and a large and representative sam-
ple of middle-aged individuals studied in three districts
of Finland. The survey methods have been carefully
standardised and comply with international recommen-
dations [22]. However, as previously mentioned, our
results are based on cross-sectional data and we cannot
determine the future diabetes and CVD risk related to
different obesity phenotypes. More sophisticated mea-
sures may have captured differences in behavioural fac-
tors, but they are labour-intensive to carry out in a
population-based survey.
Conclusions
This cross-sectional population-based study, demon-
strated a prevalence of 9-16% of a metabolically healthy
phenotype among obese individuals. Metabolic conse-
quences of obesity seem to be more adverse among
individuals with MetS. Undetected type 2 diabetes was
more prevalent among those with MetS irrespective of
BMI class. Increasing BMI had a significantly greater
effect on estimates of liver fat and future CVD risk
among those with MetS compared with participants
without MetS. The healthy obese phenotype was asso-
ciated with a better overall metabolic profile than that
observed in normal weight individuals with MetS.
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